Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer ...

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci) injection for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ...

Novo Nordisk (NVO) wins U.S. FDA nod for its Alhemo injection as a once-daily prophylaxis for bleeding prevention in patients ...

With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

A seminar titled 'Hemophilia Awareness' was held here at Govt College Women University Sialkot (GCWUS) to educate ...

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed ...

Altuviiio (efanesoctocog alfa) may work better than other treatments as a hemophilia A factor replacement therapy, a study ...

A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...